Navigating the Increasing Complexity of Drug-Biomarker Co-Development
Published: | Updated:
To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
